Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR3 | P22607 | 3/20 | 0.46 |
| ▸ | KDR | P35968 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 7/20 | 0.40 |
| ▸ | ITK | Q08881 | 4/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 4/20 | 0.39 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.39 |
| ▸ | FGFR4 | P22455 | 3/20 | 0.39 |
| ▸ | BTK | Q06187 | 9/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31655620 | 1.00 | FGFR3 (0.46) | FGFR3KDREGFRITKFGFR2 | |
| SCHEMBL22122045 | 0.86 | FGFR3 (0.55) | FGFR3KDRFGFR2FGFR1FGFR4 | |
| SCHEMBL31655628 | 0.84 | FGFR3 (0.55) | FGFR3KDREGFRITKFGFR2 | |
| SCHEMBL22149349 | 0.82 | FGFR3 (0.55) | FGFR3KDREGFRITKFGFR2 | |
| SCHEMBL31655636 | 0.82 | FGFR3 (0.55) | FGFR3KDREGFRITKFGFR2 | |
| SCHEMBL22149692 | 0.81 | FGFR3 (0.50) | FGFR3KDREGFRITKFGFR2 | |
| SCHEMBL31655616 | 0.81 | FGFR3 (0.50) | FGFR3KDREGFRITKFGFR2 | |
| SCHEMBL22149350 | 0.81 | FGFR3 (0.56) | FGFR3KDRFGFR2FGFR1FGFR4 | |
| SCHEMBL31655633 | 0.81 | FGFR3 (0.56) | FGFR3KDRFGFR2FGFR1FGFR4 | |
| SCHEMBL22149125 | 0.80 | FGFR3 (0.58) | FGFR3KDRFGFR2FGFR1FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2020131674-A1 | 7-((3,5-DIMETHOXYPHENYL)AMINO)QUINOXALINE DERIVATIVES AS FGFR INHIBITORS FOR TREATING CANCER | ARRAY BIOPHARMA INC. (US) | 2020-06-25 | — | — | WO | disclosed |